Intrinseque Health wins Singapore clinical supply chain award for fifth straight year

By AI, Created 10:26 AM UTC, May 20, 2026, /AGP/ – Intrinseque Health has been named Best Clinical Supply Chain Solutions Provider 2026 Singapore, marking the company’s fifth consecutive win. The award underscores the growing importance of reliable clinical trial supply chains as drug development grows more complex.

Why it matters: - The award highlights demand for clinical supply chain partners that can keep global drug development and clinical trials moving on time. - Intrinseque Health’s fifth straight win signals sustained recognition in a sector where execution, quality and regulatory handling can affect study timelines.

What happened: - Intrinseque Health received the Best Clinical Supply Chain Solutions Provider 2026 Singapore award. - The recognition was announced May 11, 2026. - The company said the win is its fifth in a row in this category. - Nitin Jain, President and CEO of Intrinseque Health, thanked Global Health & Pharma’s awards panel for the title.

The details: - Intrinseque Health described itself as a global clinical development support organization certified to EN ISO 13485, ISO 9001, ISO 27001 and GDPMDS standards. - The company said it supports clinical trial studies globally and has offices in the United States, the Netherlands, the United Kingdom, China, Taiwan, Korea, India, Malaysia and Singapore. - Intrinseque Health said its team is managed by drug development professionals with more than 300 years of combined experience supporting global clinical trials across therapeutic areas. - The company said it focuses on product availability and lead times, in-country sourcing versus import decisions, import regulations, IOR/EOR requirements, storage and warehousing, kitting, labelling and printing, equipment installation, calibration, validation, servicing and maintenance, local sourcing and procurement. - Intrinseque Health said it engages early with clients and uses a cost-effective clinical supply chain strategy tailored to each trial.

Between the lines: - The repeated award suggests the market values clinical supply chain providers that can combine regulatory knowledge, operational consistency and global reach. - The company’s messaging positions supply chain reliability as a patient-access issue, not just a logistics function.

What’s next: - Intrinseque Health said it aims to become a global leader in clinical trial support services. - The company said it will continue developing new solutions for clinical supply chain challenges.

The bottom line: - Intrinseque Health is using its latest award to reinforce a broader pitch: dependable clinical supply chains are now central to successful drug development.